Three entities report a passive stake above 5% in Aura Biosciences (AURA).
A Schedule 13G SEC filing reveals that ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V. collectively hold a passive stake of approximately 5.1% in Aura Biosciences (AURA). This represents 5,248,841 shares of common stock based on 103,704,809 shares outstanding as of August 6, 2026. The entities, all organized under the laws of the Netherlands, disclaim membership in a formal "group" despite making a joint filing.
Forbion Entities Reveal 5.1% Stake in Aura Biosciences via SEC Filing
Three Forbion entities, including ForGrowth III PA B.V., Forbion Growth Opportunities Fund III Cooperatief U.A., and Forbion Growth III Management B.V., have disclosed a collective beneficial ownership of 5,248,841 shares in Aura Biosciences, representing approximately 5.1% of the company's outstanding common stock. This disclosure was made through a Schedule 13G filing with the SEC on October 1, 2026, stemming from an event on September 25, 2026. The entities are based in the Netherlands and collectively hold shared voting and dispositive power over these shares, clarifying that their intent is not to change or influence company control.
Aura Biosciences, Inc.(NasdaqGM:AURA) added to S&P Biotechnology Select Industry Index
Aura Biosciences, Inc. (NasdaqGM:AURA) has been added to the S&P Biotechnology Select Industry Index. The company is a clinical-stage biotechnology firm developing precision therapies for solid tumors, with its lead candidate, bel-sar, in late-stage development for choroidal melanoma. This inclusion highlights the company's progress and recognition within the biotechnology sector.
Aura Biosciences at Morgan Stanley conference: bel-sar takes center stage
Aura Biosciences presented its investigational eye cancer therapy, bel-sar, at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting its potential to transform treatment for early choroidal melanoma by preserving vision while controlling tumors. The company is focusing on ocular oncology, with Phase III data for bel-sar expected in the second half of 2026. Aura believes bel-sar addresses a significant unmet medical need and targets a large, underserved market, despite the inherent risks of late-stage biotech development.
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences, a clinical-stage biotechnology company, announced that its CEO and President, Natalie Holles, will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. She will present during a fireside chat at 2:35 p.m. ET, which will be webcast live. The company is developing bel-sar, a first-in-class therapy for ocular cancers.
Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences announced that CEO and President Natalie Holles will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026. The company is a clinical-stage biotechnology firm developing bel-sar, a therapy for ocular cancers, with a Phase 3 study for early choroidal melanoma fully enrolled. A live webcast of the fireside chat will be available on the company's website.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement equity awards to three new executives: Erica Kratz (Chief Regulatory and Quality Officer), Susan Abu-Absi (Chief Operating Officer), and Julie Person (Chief People Officer). These awards, granted on September 1, 2026, consist of non-qualified stock options and restricted stock units, approved in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are designed to attract and retain key talent in the clinical-stage biotechnology company focused on ocular cancer therapies.
Aura CEO to speak at Morgan Stanley healthcare event Sept. 16
Aura Biosciences (NASDAQ: AURA) announced that its CEO and President, Natalie Holles, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 2:35 p.m. ET. A live webcast and a 90-day replay of the chat will be available on the company's website. Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a therapy for ocular cancers.
COO at Aura Biosciences (AURA) lands new option and RSU package
Aura Biosciences (AURA) Chief Operating Officer Susan Abu-Absi received an inducement award consisting of 265,487 stock options with an exercise price of $7.43 per share and 134,513 Restricted Stock Units (RSUs). The RSUs will vest in four annual installments starting September 15, 2027, while the stock options vest 25% on August 10, 2027, with the remainder vesting monthly over 36 installments, both subject to continued service. This equity package aims to align the COO's interests with the company's long-term performance.
Aura Biosciences Grants Inducement Equity Awards to Newly Appointed Executives
Aura Biosciences has granted inducement equity awards to its new Chief Regulatory and Quality Officer, Chief Operating Officer, and Chief People Officer on September 1, 2026. These awards, consisting of non-qualified stock options and restricted stock units, were approved by the Compensation Committee in accordance with Nasdaq rules. The company, which is developing bel-sar for ocular cancers, aims to incentivize its new executive team with these equity grants.
Aura Biosciences, Inc. SEC Filing (Aug 21, 2026)
Aura Biosciences, Inc. filed an EFFECT SEC filing which was accepted on August 21, 2026, for Form S-3 with an effectiveness date of August 20, 2026. The filing has a neutral impact and sentiment according to AI-generated analysis. The company's stock, AURA, has a market cap of $805.79 million and is ranked among top gainers in various timeframes.
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell
Wall Street Zen has downgraded Aura Biosciences (NASDAQ:AURA) from "hold" to "sell" amidst mixed analyst coverage and the company's recent financial performance. Aura Biosciences reported a quarterly loss of $0.48 per share, missing consensus estimates, and has cut 20% of its workforce to preserve cash for its late-stage eye-cancer trial. The stock's price performance reflects these concerns, though institutional investors hold a significant stake.
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap
A Schedule 13G/A filing indicates that Frazier Life Sciences-affiliated funds and individuals have updated their ownership report for Aura Biosciences (AURA). Frazier Life Sciences Public Fund, L.P. directly holds 5.6% of Aura Biosciences' common stock, and other Frazier funds also hold significant shares. The report also highlights that prefunded warrants held by these funds are subject to a 9.99% beneficial ownership limitation to prevent exceeding this threshold upon exercise.
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership
Long Focus Capital Management, LLC and John Helmers have reported a 4.9% beneficial ownership stake in Aura Biosciences, Inc. (AURA) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 5,119,582 shares of common stock, with shared voting and dispositive power. The filing indicates that no single client of Long Focus Capital Management, LLC owns more than 5% of Aura Biosciences' class of securities.
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)
This article highlights bullish sentiments from analysts for two healthcare stocks: Aura Biosciences Inc (AURA) and Corbus Pharmaceuticals (CRBP). LifeSci Capital and H.C. Wainwright maintained Buy ratings for Aura Biosciences, projecting a significant upside. Mizuho Securities and RBC Capital also reiterated Buy ratings for Corbus Pharmaceuticals, anticipating a substantial increase from current levels.
HC Wainwright Raises Earnings Estimates for Aura Biosciences
HC Wainwright has increased its earnings estimates for Aura Biosciences (NASDAQ:AURA), projecting a smaller loss for Q3 2026 and forecasting positive EPS by 2030. Despite maintaining a "Buy" rating, the firm lowered its price target to $18, reflecting a more cautious valuation. Aura Biosciences reported a larger-than-expected quarterly loss of -$0.48, missing consensus estimates.
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift
H.C. Wainwright has lowered its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24, while maintaining a Buy rating. This adjustment comes as Aura Biosciences shifts its strategic focus and capital allocation towards ocular oncology programs, particularly after completing enrollment for its Phase 3 CoMpass trial. The company is also scaling back investment in its non-muscle invasive bladder cancer program, now modeling it for a potential out-licensing scenario.
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person
Aura Biosciences, Inc. (AURA) has filed a Form 3, an initial statement of beneficial ownership, for its new Chief People Officer, Julie Person. This filing registers her status as an officer of the company, but it indicates no transactions or current holdings of company securities by her at this time. The document confirms her role and obligations for future reporting of beneficial ownership.
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3
Aura Biosciences (AURA) Chief Operating Officer Susan Abu-Absi has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. This filing establishes her insider status for future reporting but does not report any stock transactions or derivative positions at this time. The document confirms her role as COO and indicates she is not a 10% owner.
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24
H.C. Wainwright has revised its target price for AURA Biosciences, Inc., reducing it from $24 to $18. This change indicates a lowered valuation expectation for the company by the financial institution. The article itself is very brief, mainly serving as a headline for this analyst action.
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18
H.C. Wainwright has reiterated its Buy rating on Aura Biosciences (AURA.US) and maintained its price target of $18. This indicates the firm's continued confidence in the company's prospects. Investors will be watching for further developments from Aura Biosciences.
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00
HC Wainwright has reduced its price target for Aura Biosciences (NASDAQ:AURA) to $18.00 from $24.00, while maintaining a "Buy" rating, indicating a potential upside of 131.1% from its current price. This adjustment comes as Aura Biosciences reported a wider-than-expected quarterly loss of $0.48 per share. Despite the lowered price target, the firm's outlook remains positive, contrasting with the broader analyst consensus of "Hold" and an average target of $17.50.
Aura Biosciences Releases Q2 2026 Financial Results
Aura Biosciences, Inc. (AURA) reported a net loss of $45.6 million and a loss of $0.48 per share for Q2 2026, slightly wider than the previous year, as it continues to invest in developing precision therapies for solid tumors. Despite the losses common for clinical-stage biotech firms, Wall Street analysts maintain a positive outlook with 8 buy ratings and 1 hold rating. This reflects confidence in the company's development programs, even through the capital-intensive phases of clinical trials.
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS
Aura Biosciences (NASDAQ: AURA) reported a quarterly loss of $0.48 per share, missing analysts' consensus estimates by $0.10. Shares traded down at $7.55, significantly below its 52-week high, with institutional investors holding a large majority of outstanding shares. Despite mixed analyst sentiment, the company continues developing its lead product candidate, AU-011, for choroidal melanoma and other cancer treatments.
Form 8K Aura Biosciences Inc For: 11 August By Investing.com
This article is a brief financial market update from Investing.com, announcing that Aura Biosciences Inc. has filed a Form 8K on August 11. It also includes the current stock performance for AURA, showing a 4.94% increase.
Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount
Aura Biosciences reported a wider net loss of $79.3 million for the first half of 2026, compared to $54.5 million in 2025, due to increased research and development and administrative expenses. Despite mounting losses, the company significantly boosted its liquidity by raising $280.8 million in net proceeds from a May 2026 follow-on offering, which included the repurchase of 6,922,870 shares. Aura Biosciences plans to fund operations for at least 12 months with its $323.8 million cash, cash equivalents, and marketable securities, while refocusing on ocular oncology and implementing a 20% workforce reduction.
AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029
Aura Biosciences (AURA) has fully enrolled its Phase 3 Compass trial for bel-sar in early choroidal melanoma, with topline data anticipated in the second half of 2027. The company's strategic shift to ocular oncology has extended its cash runway into the first half of 2029. Additionally, interim data from its NMIBC program show strong early efficacy and safety.
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aura Biosciences announced its Q2 2026 financial results, highlighting the full enrollment of its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in H2 2027. The company is strategically focusing resources on ocular oncology, deprioritizing its NMIBC program despite encouraging interim data, and has undergone an organizational restructuring including leadership appointments and a 20% workforce reduction to extend its cash runway into H1 2029. The financial report shows a net loss of $45.6 million for the quarter.
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary
Aura Biosciences, Inc. reported a Q2 2026 net loss of $45.6M, an increase from $27.0M in Q2 2025, with a diluted loss per share of $(0.48). The company remains pre-revenue but is advancing its bel-sar clinical trials, refocusing on ocular oncology, and has secured funding to operate into H1 2029 through recent offerings.
Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss
Aura Biosciences reported a net loss of $45.6 million for Q2 2026, an increase from $27.0 million a year prior, despite having $323.8 million in cash, cash equivalents, and marketable securities. The company announced a restructuring, including a 20% workforce reduction, to extend its cash runway into the first half of 2029 and is prioritizing ocular oncology. Insider trading showed 7 sales and no purchases in the last six months, while institutional investors had mixed activity with some increasing and others decreasing their positions.
Responsive Playbooks and the AURA Inflection
This article provides an in-depth analysis of Aura Biosciences Inc. (NASDAQ: AURA), highlighting strong sentiment across all horizons and an exceptional 58.5:1 risk-reward short setup. It details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide traders on potential entry, target, and stop-loss levels. The analysis suggests an overweight bias for AURA.
AURA Q2'26 Earnings: EPS estimate is (0.38) USD
Aura Biosciences, Inc. (AURA) is scheduled to release its Q2'26 earnings on August 06. Analysts estimate the company will report 0 USD in revenue and an EPS of (0.38) USD for the quarter. The article provides a historical overview of reported and estimated EPS values for previous quarters.
Understanding the Setup: (AURA) and Scalable Risk
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA), highlighting a strong near-term sentiment that could lead to a long-term positive bias. It identifies support and resistance levels, noting an exceptional 58.0:1 risk-reward setup targeting a 16.7% gain. The piece also outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, complete with entry points, targets, and stop losses.
BlackRock (AURA holder) discloses 4.4% Aura Biosciences stake in amended filing
BlackRock, Inc. has filed an amended ownership report (SCHEDULE 13G/A) for Aura Biosciences Inc. common stock, disclosing a beneficial ownership of 4,582,436 shares, which represents a 4.4% stake in the company. BlackRock maintains sole voting power over 4,528,500 shares and sole dispositive power over all 4,582,436 shares. This filing indicates that the holdings are for investment purposes and do not aim to change or influence control of Aura Biosciences.
Aura Biosciences Inc (AURA) Institutional Confidence
This article provides details on the institutional confidence in Aura Biosciences Inc (AURA), listing key institutional shareholders and their holdings. It shows that Frazier Life Sciences Management, L.P. holds the largest stake. The data includes the number of shares held and the percentage change in holdings for each institution.
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Aura Biosciences Inc (AURA), listing its major shareholders and their proportions, as well as the types of shareholders. It also provides institutional shareholding data over several quarters and recent shareholder activity with specific dates and changes, along with related ETF holdings.
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Aura Biosciences Inc (AURA) focusing on its dividend and stock split history, noting that no dividends have been distributed in the past five years. It presents current stock performance data, market capitalization, and links to various company financial and analytical information.
TradingKey
This article provides a detailed cash flow statement for Aura Biosciences Inc. (AURA), covering quarterly and annual data for operating, investing, and financing activities. It also includes frequently asked questions explaining the different types of cash flows and Aura Biosciences' specific figures for operating, capital expenditures, financing, and free cash flow in recent periods.
Aura Biosciences Inc (AURA) Valuation: PE, PB & Fair Value Analysis
This article provides a brief valuation analysis of Aura Biosciences Inc (AURA), detailing its current stock price, market capitalization loss, and an overview of its financial data. It notes that relevant data for P/E, P/B, and P/CF ratios have not yet been disclosed by the company. The page serves as a financial information portal for AURA, offering various sub-sections like earnings forecasts and risk assessment.
Aura Biosciences Inc (AURA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aura Biosciences Inc (AURA), detailing various indicators and moving averages. It offers insights into the stock's current technical signals, which are predominantly neutral with some buy signals from moving averages. The analysis is intended for investment reference and highlights components like MACD, RSI, and moving averages MA5 through MA200.
AURA|Aura Biosciences Inc|Price:7.050|Chg%:-0.150
This article provides an overview of Aura Biosciences Inc (AURA) stock performance, showing a closing price of 7.050 USD with a -2.08% change. It details how TradingKey generates its stock scores across various dimensions like financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk management, although AURA currently lacks a score due to insufficient data. The article also includes frequently asked questions explaining the methodology behind each scoring dimension.
Aura Biosciences, Inc. Revenue Breakdown – BOATS:AURA
This article provides a revenue breakdown for Aura Biosciences, Inc. (AURA) as presented on TradingView. It indicates that the financial data, including top segments and regional performance, is available by source and country, accessible through various financial tools and data providers. The article serves as a directory to financial specifics for the company on the TradingView platform.
AURA|Aura Biosciences Inc|Price:7.050|Chg%:-0.150
Aura Biosciences Inc. (AURA) closed at $7.05, down 2.08%. The company is a clinical-stage biotechnology firm developing precision therapies for solid tumors, with its lead candidate bel-sar in late-stage development for choroidal melanoma. Analysts maintain a "Buy" rating with an average target price of $18.80, indicating a significant upside.
The Technical Signals Behind (AURA) That Institutions Follow
A recently generated AI analysis for Aura Biosciences Inc. (NASDAQ: AURA) indicates weak near-term sentiment with a support test underway. The report outlines three institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis and specific risk-reward targets. Full access to real-time signals and personalized alerts requires registration.
Price to earnings forward of Aura Biosciences, Inc. – NASDAQ:AURA
This page displays the "Price to earnings forward" metric for Aura Biosciences, Inc. (NASDAQ: AURA). It appears to be a financial data point provided by TradingView, sourcing data from ICE Data Services and FactSet. The core content focuses solely on this specific financial metric for the company.
Enterprise value to EBITDA forward of Aura Biosciences, Inc. – NASDAQ:AURA
This article focuses on the enterprise value to EBITDA forward metric for Aura Biosciences, Inc. (NASDAQ: AURA). It appears to be a financial data entry page, devoid of narrative content beyond the headline. The page structure suggests it's part of a larger financial information platform, providing specific metrics for this biotechnology company.
Price to sales forward of Aura Biosciences, Inc. – NASDAQ:AURA
This article provides a brief mention of Aura Biosciences, Inc. (NASDAQ: AURA) and its "Price to sales forward" metric within the context of TradingView's financial data platform. It highlights that the market was closed at the time of the article and provides no specific numerical data for the metric itself. The content is primarily navigation and boilerplate from TradingView.
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Aura Biosciences, Inc. has announced the appointment of Jeremy Bender, Ph.D., M.B.A., to its Board of Directors. Dr. Bender brings extensive experience in advancing innovative therapies through development and commercialization, having previously served as CEO of Day One Biopharmaceuticals. His expertise is expected to be invaluable as Aura Biosciences progresses towards potential regulatory approval of bel-sar for early choroidal melanoma.
Jeremy Bender joins Aura Biosciences (NASDAQ: AURA) board as independent director
Aura Biosciences (NASDAQ: AURA) has appointed Jeremy Bender, Ph.D., M.B.A., as a Class II independent director to its Board of Directors, expanding the board from six to seven members. Dr. Bender will also serve on the Compensation and Nominating and Corporate Governance Committees and will receive initial equity awards including 60,000 stock options and 30,000 restricted stock units, along with an annual board retainer. His appointment, effective July 7, 2026, leverages his extensive biotechnology leadership experience as Aura progresses its lead candidate, bel-sar, through late-stage development for choroidal melanoma.
Form 4 Aura Biosciences Inc For: 8 July By Investing.com
This article reports on a Form 4 filing for Aura Biosciences Inc. related to activity on July 8. The news, published by Investing.com, indicates routine financial disclosure for the company.
